Show simple item record

dc.contributor.authorFields, P
dc.contributor.authorTownsend, W
dc.contributor.authorWebb, A
dc.contributor.authorCounsell, N
dc.contributor.authorPocock, C
dc.contributor.authorSmith, P
dc.contributor.authorJack, A
dc.contributor.authorEl-Mehidi, N
dc.contributor.authorJohnson, P
dc.contributor.authorRadford, John A
dc.contributor.authorLinch, D
dc.contributor.authorCunnningham, D
dc.date.accessioned2013-12-20T11:10:25Z
dc.date.available2013-12-20T11:10:25Z
dc.date.issued2013-11-12
dc.identifier.citationDe Novo treatment of diffuse large B-cell lymphoma with Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in patients with cardiac comorbidity: A United Kingdom National Cancer Research Institute trial. 2013: J Clin Oncolen
dc.identifier.issn1527-7755
dc.identifier.pmid24220559
dc.identifier.doi10.1200/JCO.2013.49.7586
dc.identifier.urihttp://hdl.handle.net/10541/308809
dc.description.abstractThe treatment of patients with diffuse large B-cell lymphoma (DLBCL) with cardiac comorbidity is problematic, because this group may not be able to receive anthracycline-containing chemoimmunotherapy. We designed a single-arm phase II multicenter trial of rituximab, gemcitabine, cyclophosphamide, vincristine, and prednisolone (R-GCVP) in patients considered unfit for anthracycline-containing chemoimmunotherapy because of cardiac comorbidity.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen
dc.titleDe Novo treatment of diffuse large B-cell lymphoma with Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in patients with cardiac comorbidity: A United Kingdom National Cancer Research Institute trial.en
dc.typeArticleen
dc.contributor.departmentGuys and St Thomas' and King's College Hospitals, London, UK.en
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractThe treatment of patients with diffuse large B-cell lymphoma (DLBCL) with cardiac comorbidity is problematic, because this group may not be able to receive anthracycline-containing chemoimmunotherapy. We designed a single-arm phase II multicenter trial of rituximab, gemcitabine, cyclophosphamide, vincristine, and prednisolone (R-GCVP) in patients considered unfit for anthracycline-containing chemoimmunotherapy because of cardiac comorbidity.


This item appears in the following Collection(s)

Show simple item record